These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25750634)

  • 21. Recognition and Management of Antipsychotic-Induced Parkinsonism in Older Adults: A Narrative Review.
    Wisidagama S; Selladurai A; Wu P; Isetta M; Serra-Mestres J
    Medicines (Basel); 2021 May; 8(6):. PubMed ID: 34073269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of tardive dyskinesia: an updated review of the literature.
    Lanning RK; Zai CC; Müller DJ
    Pharmacogenomics; 2016 Aug; 17(12):1339-51. PubMed ID: 27469238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR
    Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unilateral Parkinson's disease and contralateral tardive dyskinesia: a unique case with successful therapy that may explain the pathophysiology of these two disorders.
    Fahn S; Mayeux R
    J Neural Transm Suppl; 1980; (16):179-85. PubMed ID: 6933220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
    Gil S; Park C; Lee J; Koh H
    Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.
    Sgambato V; Tremblay L
    J Neural Transm (Vienna); 2018 Aug; 125(8):1145-1156. PubMed ID: 29502255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson's Disease.
    Blosser JA; Podolsky E; Lee D
    Exp Neurobiol; 2020 Aug; 29(4):273-284. PubMed ID: 32921640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
    Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterizing the differential roles of striatal 5-HT
    Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
    Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia.
    Miller R; Chouinard G
    Biol Psychiatry; 1993 Nov; 34(10):713-38. PubMed ID: 7904833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia.
    Jeong EH; Sunwoo MK; Song YS
    Front Neurol; 2018; 9():1133. PubMed ID: 30619078
    [No Abstract]   [Full Text] [Related]  

  • 40. Historical perspectives on tardive dyskinesia.
    Caroff SN; Ungvari GS; Cunningham Owens DG
    J Neurol Sci; 2018 Jun; 389():4-9. PubMed ID: 29454494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.